Tumor Biology

, Volume 35, Issue 5, pp 4741–4756 | Cite as

The effect of CYP1A1 and CYP1A2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis

  • Huiping Xue
  • Yan Lu
  • Zeyun Xue
  • Bing Lin
  • Jinxian Chen
  • Feng Tang
  • Gang Huang
Research Article


Potential Cytochrome P450s (CYPs) 1A1 MspI, 1A1 Ile462Val, 1A2*1 F, and/or 1A2*1C polymorphisms have been implicated in gastric cancer risk among different ethnicities. We aimed to explore the effect of CYP 1A1 MspI, 1A1 Ile462Val, 1A2*1 F, and/or 1A2*1C polymorphisms on the susceptibility to gastric cancer among different ethnicities through a systematic review and meta-analysis. Each initially included article was scored for quality appraisal. Desirable data were extracted and registered into databases. A number of 11 studies were ultimately eligible for the meta-analysis of CYP1A1 MspI polymorphism, eight studies for the meta-analysis of 1A1 Ile462Val polymorphism, and two studies for the meta-analysis of 1A2*1 F polymorphism. None of genetic model was evidently suggested, and thus all the genetic models were presented. Potential sources of heterogeneity were sought out via subgroup and sensitivity analyses, and publication biases were estimated. In our meta-analysis, significant results could be found in mutational heterozygous CT genotype, compared with wild TT genotype, among large sample size subgroup for CYP1A1 MspI polymorphism. Regarding CYP1A1 Ile462Val polymorphism, no statistically significant results could be found. For CYP1A2*1 F polymorphism, mutational heterozygous AC genotype, compared with wild-type AA, has deleterious effects, whereas mutational homozygous CC genotype, compared with mutational heterozygous type AC, has protective effects but lacks statistically significant difference despite its a proximity to 0.05. Combined mutational homozygous CC genotype and wild-type homozygous AA, compared with mutational heterozygous AC genotype, has protective effects. Our meta-analysis suggests no associations between CYP1A1 Ile462Val polymorphism and gastric cancer, but possible associations between CYP1A1 MspI and CYP1A2*1 F polymorphisms and gastric cancer, which needs to be further reinforced or refuted among different ethnicities in well-designed large-scale high-quality studies.


Cytochrome P450s (CYPs) Gene Polymorphism Association Gastric cancer 



The authors would to acknowledge their grant sponsors, namely, the National Natural Science Foundation of China (grants 30830038, 30970842, and 81071180), the “973” Project (2012CB932604), the New Drug Discovery Project (2012ZX09506-001-005), the Key Project of Science and Technology Commission of Shanghai Municipality (grants 10JC1410000), and the Shanghai Leading Academic Discipline Project (grant S30203).

The role of funding is to provide financial support for the authors' searching of articles online and copying of the searched articles.

Conflicts of interest


Supplementary material

13277_2014_1620_MOESM1_ESM.docx (15 kb)
ESM 1 (DOCX 15 kb)
13277_2014_1620_MOESM2_ESM.doc (49 kb)
Table S1 Scales for quality assessment (DOC 49 kb)


  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.CrossRefPubMedGoogle Scholar
  2. 2.
    Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, et al. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology. 2002;123:1793–803.CrossRefPubMedGoogle Scholar
  3. 3.
    Xue H, Lin B, Ni P, Xu H, Huang G. Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol. 2010;25(10):1604–17.CrossRefPubMedGoogle Scholar
  4. 4.
    Xue H, Liu J, Lin B, Wang Z, Sun J, et al. A Meta-analysis of interleukin-8-251 promoter polymorphism associated with gastric cancer risk. PLoS One. 2012;7(1):e28083.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gonzalez FJ. The role of carcinogen-metabolizing enzyme polymorphisms in cancer susceptibility. Reprod Toxicol. 1997;11:397–412.CrossRefPubMedGoogle Scholar
  6. 6.
    Constable A, Varga N, Josephy PD, Guy P, Turesky RJ. Evaluation of Escherichia coli DJ4309 expressing human P450 1A2 in mutagenicity testing of complex food mixtures. Mutat Res. 1999;442(2):79–87.CrossRefPubMedGoogle Scholar
  7. 7.
    Al-Buheissi SZ, Cole KJ, Hewer A, Kumar V, Bryan RL, Hudson DL, et al. The expression of xenobiotic-metabolizing enzymes in human prostate and in prostate epithelial cells (PECs) derived from primary cultures. Prostate. 2006;66(8):876–85.CrossRefPubMedGoogle Scholar
  8. 8.
    McManus ME, Burgess WM, Veronese ME, Huggett A, Quattrochi LC, Tukey RH. Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450. Cancer Res. 1990;50(11):3367–76.PubMedGoogle Scholar
  9. 9.
    Pavanello S, Clonfero E. Biological indicators of genotoxic risk and metabolic polymorphisms. Mutat Res. 2000;463:285–308.CrossRefPubMedGoogle Scholar
  10. 10.
    Wright CM, Larsen JE, Colosimo ML, Barr JJ, Chen L, McLachlan RE, et al. Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancer. Eur Respir J. 2010;35(1):152–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Sachse C, Bhambra U, Smith G, et al. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol. 2003;55:68–76.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Olivieri EH, da Silva SD, Mendonça FF, Urata YN, Vidal DO, Faria Mde A, et al. CYP1A2*1C, CYP2E1*5B, and GSTM1 polymorphisms are predictors of risk and poor outcome in head and neck squamous cell carcinoma patients. Oral Oncol. 2009;45(9):e73–9. doi: 10.1016/j.oraloncology.2009.03.004.CrossRefPubMedGoogle Scholar
  13. 13.
    Darazy M, Balbaa M, Mugharbil A, Saeed H, Sidani H, Abdel-Razzak Z. CYP1A1, CYP2E1, and GSTM1 gene polymorphisms and susceptibility to colorectal and gastric cancer among Lebanese. Genet Test Mol Biomarkers. 2011;15(6):423–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Luo YP, Chen HC, Khan MA, Chen FZ, Wan XX, Tan B, et al. Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility. Tumour Biol. 2011;32(1):215–22.CrossRefPubMedGoogle Scholar
  15. 15.
    Kobayashi M, Otani T, Iwasaki M, Natsukawa S, Shaura K, Koizumi Y, et al. Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of stomach cancer: a hospital-based case–control study in Japan. Gastric Cancer. 2009;12(4):198–205.CrossRefPubMedGoogle Scholar
  16. 16.
    Malik MA, Upadhyay R, Mittal RD, Zargar SA, Modi DR, Mittal B. Role of xenobiotic-metabolizing enzyme gene polymorphisms and interactions with environmental factors in susceptibility to gastric cancer in Kashmir Valley. J Gastrointest Cancer. 2009;40(1–2):26–32.CrossRefPubMedGoogle Scholar
  17. 17.
    Boccia S, Sayed-Tabatabaei FA, Persiani R, Gianfagna F, Rausei S, Arzani D, et al. Polymorphisms in metabolic genes, their combination and interaction with tobacco smoke and alcohol consumption and risk of gastric cancer: a case–control study in an Italian population. BMC Cancer. 2007;7:206.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Wideroff L, Vaughan TL, Farin FM, Gammon MD, Risch H, Stanford JL, et al. GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. Cancer Detect Prev. 2007;31(3):233–6.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    González A, Ramírez V, Cuenca P, Sierra R. Polymorphisms in detoxification genes CYP1A1, CYP2E1, GSTT1 and GSTM1 in gastric cancer susceptibility. Rev Biol Trop. 2004;52(3):591–600. Spanish.PubMedGoogle Scholar
  20. 20.
    Lee K, Cáceres D, Varela N, Csendes DA, Ríos RH, Quiñones SL. Allelic variants of cytochrome P4501A1 (CYP1A1), glutathione S transferase M1 (GSTM1) polymorphisms and their association with smoking and alcohol consumption as gastric cancer susceptibility biomarkers. Rev Med Chil. 2006;134(9):1107–15. Spanish.CrossRefPubMedGoogle Scholar
  21. 21.
    Agudo A, Sala N, Pera G, Capellá G, Berenguer A, García N, et al. Polymorphisms in metabolic genes related to tobacco smoke and the risk of gastric cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2006;15(12):2427–34.CrossRefPubMedGoogle Scholar
  22. 22.
    Ma JX, Zhang KL, Liu X, Ma YL, Pei LN, Zhu YF, et al. Concurrent expression of aryl hydrocarbon receptor and CYP1A1 but not CYP1A1 MspI polymorphism is correlated with gastric cancers raised in Dalian. China Cancer Lett. 2006;240(2):253–60.CrossRefPubMedGoogle Scholar
  23. 23.
    Shen J, Wang RT, Xu YC, Wang LW, Wang XR. Interaction models of CYP1A1, GSTM1 polymorphisms and tobacco smoking in intestinal gastric cancer. World J Gastroenterol. 2005;11(38):6056–60.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Li H, Chen XL, Li HQ. Polymorphism of CYPIA1 and GSTM1 genes associated with susceptibility of gastric cancer in Shandong Province of China. World J Gastroenterol. 2005;11(37):5757–62.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Nan HM, Song YJ, Yun HY, Park JS, Kim H. Effects of dietary intake and genetic factors on hypermethylation of the hMLH1 gene promoter in gastric cancer. World J Gastroenterol. 2005;11(25):3834–41.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Roth MJ, Abnet CC, Johnson LL, Mark SD, Dong ZW, Taylor PR, et al. Polymorphic variation of Cyp1A1 is associated with the risk of gastric cardia cancer: a prospective case-cohort study of cytochrome P-450 1A1 and GST enzymes. Cancer Causes Control. 2004;15(10):1077–83.CrossRefPubMedGoogle Scholar
  27. 27.
    Suzuki S, Muroishi Y, Nakanishi I, Oda Y. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer. J Gastroenterol. 2004;39(3):220–30.CrossRefPubMedGoogle Scholar
  28. 28.
    Zhou T, Fan W, Han W, Gao YJ, Yuan MB, Li JM, et al. Genotypes of cytochrome P450 1A1 and frequent risk factors of gastric cancer in the Han people in China. J Shandong Univ Health Sci. 2007;45(1):71–5. Chinese.Google Scholar
  29. 29.
    Shen HX, Fu Y, Yuan Y, Di YL, Fu Q, Zhang KL, et al. cytochrome P450 1A1genetic polymorphisms and gastric cancer susceptibility study. J Dalian Med Univ. 2005;27(1):22–4. 67. [Chinese].Google Scholar
  30. 30.
    Shen J, Wang RT, Xin HX, Wang LW, Wang CX, Wang BY, et al. Research on the interaction models of cytochrome P450 1A1 polymorphism(s) in the agents of stomach cancer. Chin J Prev Med. 2001;35(3):167–70 [Chinese].Google Scholar
  31. 31.
    Huang X, Tang GD, Jiang HX, Huang JA, Tan ZR, Liang ZH, et al. ssociation between genetic polymorphisms of CYP1A1, GSTM1 and gastric cancer susceptibility in Guangxi Province of China. Chin J Modern Med. 2012;22(8):27–30 [Chinese].Google Scholar
  32. 32.
    Huang X, Tang GD, Jiang HX, Huang JA, Tan ZR, Liang ZH, et al. Association between genetic polymorphisms of CYP 1A1 and gastric cancer susceptibility in Guangxi province of China. Int J Dig Dis. 2010;30(5):304–6. [Chinese] doctoral dissertation.Google Scholar
  33. 33.
    Shen J, Wang RT, Xin HX, Wang LW, Wang CX, Wang BY, et al. Case–control study of the polymorphisms of phase I and phase II metabolic genes and stomach cancer susceptibility. Tumor. 2002;22(1):9–13.Google Scholar
  34. 34.
    Li HQ, Zhou T, Wen PE, Yang RS, Jin SK. A Study of CYP1A1 and GSTM1 genotypes associated with susceptibility to gastric cancer, chronic atrophic gastritis and gastric ulcer diseases. China Cancer. 2002;11(1):25–8.Google Scholar
  35. 35.
    Han F, Wang X, Wang X, Luo Y, Li W. Meta-analysis of the association of CYP1A1 polymorphisms with gastric cancer susceptibility and interaction with tobacco smoking. Mol Biol Rep. 2012;39(8):8335–44.CrossRefPubMedGoogle Scholar
  36. 36.
    Guo R, Guo X. Quantitative assessment of the associations between CYP1A1 polymorphisms and gastric cancer risk. Tumour Biol. 2012;33(4):1125–32.CrossRefPubMedGoogle Scholar
  37. 37.
    Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, et al. Systematic review and metaanalysis of the association between{h}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol. 2005;162(3):201–11.CrossRefPubMedGoogle Scholar
  38. 38.
    Camargo MC, Mera R, Correa P, Peek Jr RM, Fontham ET, et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(9):1674–87.CrossRefPubMedGoogle Scholar
  39. 39.
    Xue H, Ni P, Lin B, Xu H, Huang G. X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and gastric cancer risk: a HuGE review and meta-analysis. Am J Epidemiol. 2011;173(4):363–75.CrossRefPubMedGoogle Scholar
  40. 40.
    Xue H, Lu Y, Lin B, An J, Chen J, Tang F, et al. The Effect of XPD/ERCC2 Polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis. PLoS One. 2012;7(9):e43431.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Xue H, Wang YC, Lin B, An J, Chen L, Chen J, et al. A meta-analysis of interleukin-10-592 promoter polymorphism associated with gastric cancer risk. PLoS One. 2012;7(7):e39868.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Xue H, Lin B, An J, Zhu Y, Huang G. Interleukin-10-819 promoter polymorphism in association with gastric cancer risk. BMC Cancer. 2012;12(1):102.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Ioannidis JP, Boffetta P, Little J, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol. 2008;37:120–32.CrossRefPubMedGoogle Scholar
  44. 44.
    Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J. How should we use information about HWE in the meta-analyses of genetic association studies? Int J Epidemiol. 2008;37(1):136–46.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Institution of Digestive DiseaseShanghai Jiao Tong University School of MedicineShanghaiChina
  2. 2.Key Laboratory of Gastroenterology & HepatologyMinistry of Health (Shanghai Jiaotong University)ShanghaiChina
  3. 3.Department of Medicine, International Peace Hospital for the Protection of Mother and Child Health, School of MedicineShanghai Jiao Tong UniversityShanghaiChina
  4. 4.Shanghai High SchoolShanghaiChina
  5. 5.Division of Nutrition, Zhongshan HospitalFudan University School of MedicineShanghaiChina
  6. 6.Department of General SurgeryRenji HospitalShanghaiChina
  7. 7.Division of Pathology, Huashan Hospital, School of MedicineFudan University School of MedicineShanghaiChina
  8. 8.Department of Nuclear Medicine, Renji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
  9. 9.Institute of Health Sciences, Shanghai Jiao Tong University School of Medicine (SJTUSM) & Shanghai Institutes for Biological Sciences (SIBS)Chinese Academy of Sciences (CAS)ShanghaiChina

Personalised recommendations